The life sciences is a vast and increasingly diverse sector enabled by the rapid acceleration of new biological, chemical, digital and manufacturing technologies and the demand for therapies that not only manage chronic conditions, but also provide opportunities for a cure. Companies in the biotechnology, pharmaceutical, medical device and testing/diagnostics industries require access to scientific, drug development, engineering, commercial and GMP manufacturing talent; proximity to research centers and innovation ecosystems; the availability of specialized facilities; and the ability to bring new therapies to market swiftly and cost-effectively.
BLS & Co. helps clients select locations for administrative, research, development and manufacturing facilities, as well as corporate headquarters, and works with companies to obtain economic development incentives. Our services include:
We are best known for the breadth and sophistication of our incentives advisory services and have been involved in transactions in almost every state. Through our international partners we are also able to serve clients elsewhere in North and South America as well as Europe and Asia.
BLS & Co. served as site selection and incentives consultant on two major projects for BMS, including a complex and highly competitive nationwide search for the location of a new $750 million biologics facility.
BLS & Co. served as site selection and incentives consultant for Bristol-Myers Squibb's new North American Capability Center (NACC) in Tampa, FL. BMS’ goal for the NACC was to house key enterprise services—technology, finance, and accounting—together with research and analytics, and to do so in a cost-effective market. The NACC project required BLS & Co. to identify and prove out low-cost, yet high-quality, markets with diverse pools of talent.
BLS & Co. managed a team of brokers, designers, and the company’s own human resource, technology, and function heads during an engagement that resulted in the successful site selection, incentive agreement, staffing, and opening of the NACC—all within a nine-month window.
Our firm also served as site selection and incentives consultant during a complex and highly competitive nationwide search for the location of a new $750 million, large-scale multi-product bulk biologics facility in Devens, MA. The facility (the largest capital investment in BMS history) supports the production of ORENCIA (R), the company's biologic therapy for rheumatoid arthritis.
Consulting for the NACC in Tampa resulted in...
Consulting for the Biologics Facility in MA resulted in...
BLS & Co. serves as location and incentives advisor to biotechnology industry leader Genentech, the South San Francisco-based member of the Roche Group.
BLS & Co. serves as location and incentives advisor to biotechnology industry leader Genentech, the South San Francisco-based member of the Roche Group. Genentech develops, manufactures and commercializes medicines to treat patients worldwide with serious medical conditions. During our most recent engagement for Genentech, BLS & Co. managed a nationwide search for a second location for their Access Solutions Patient Service Center. Access Solutions employees help patients understand their insurance benefits; find ways to help those who cannot afford their Genentech medicines; and work with doctors and pharmacists to deliver medicines to patients. With the advice and guidance of the firm, Genentech selected Portland, OR for this mission critical operation, which opened for business in May 2019. The new Portland Patient Access Center employs approximately 175 full-time specialists and an almost equal number of contingent employees during the peak insurance benefit open season. The firm also advised Genentech on an Oregon Business Retention Program (BEP) grant and various market-entry strategies.
BLS & Co. advised global pharmaceutical leader Eli Lilly & Co. on multiple competitive site searches for its new next-generation production facilities both in the U.S. and Europe.
BLS & Co. advised global pharmaceutical leader Eli Lilly & Co. on its competitive nationwide site search for its new next-generation production facility. After a competitive evaluation of multiple locations across the U.S., Eli Lilly selected a Research Triangle site in Durham County, NC, for the new $474 million facility. The company plans to hire 460 new staff, ranging from scientists and engineers, to QC staff and plant operators. The project was actively supported by the State and County.